Analysts Set Gilead Sciences, Inc. (NASDAQ:GILD) PT at $96.43

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twenty-seven research firms that are presently covering the firm, MarketBeat.com reports. Twelve analysts have rated the stock with a hold recommendation, twelve have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $96.43.

Several research analysts have weighed in on GILD shares. Wolfe Research began coverage on shares of Gilead Sciences in a report on Friday, November 15th. They set an "outperform" rating and a $110.00 price objective on the stock. Mizuho upped their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a report on Thursday, November 21st. Leerink Partners upgraded Gilead Sciences from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Piper Sandler increased their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Thursday, November 7th.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares of the company's stock, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the business's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares of the company's stock, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 447,234 shares of company stock valued at $41,288,086 over the last quarter. Company insiders own 0.16% of the company's stock.

Institutional Investors Weigh In On Gilead Sciences

Several large investors have recently added to or reduced their stakes in GILD. State Street Corp grew its stake in Gilead Sciences by 1.4% in the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock worth $5,044,795,000 after buying an additional 841,776 shares in the last quarter. Wellington Management Group LLP grew its position in Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock worth $2,900,921,000 after acquiring an additional 11,665,593 shares in the last quarter. FMR LLC increased its stake in Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock valued at $2,780,329,000 after acquiring an additional 14,680,161 shares during the last quarter. Geode Capital Management LLC raised its position in Gilead Sciences by 2.1% during the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company's stock valued at $2,302,119,000 after purchasing an additional 574,421 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in Gilead Sciences by 0.8% during the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock worth $851,743,000 after purchasing an additional 93,068 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Up 0.3 %

Gilead Sciences stock traded up $0.24 during midday trading on Friday, reaching $91.86. The stock had a trading volume of 7,515,462 shares, compared to its average volume of 7,068,425. The company has a fifty day moving average price of $89.96 and a two-hundred day moving average price of $79.67. Gilead Sciences has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $114.48 billion, a P/E ratio of 1,020.61, a PEG ratio of 2.38 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the previous year, the company posted $2.29 earnings per share. The company's quarterly revenue was up 7.0% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences will post 4.35 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. Gilead Sciences's dividend payout ratio is presently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.